Semnur Pharmaceuticals Begins Pivotal Phase 3 Trial For SP-102 In Patients With Lumbar Radicular Pain/Sciatica
« back

SP-102 Granted Fast Track Designation From The FDA

Semnur Pharmaceuticals Announces The Launch Of The New Clinical Trial Website At
Mountain View, Calif., Jan 7, 2018 /PRNewswire/ – Semnur Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company focused on developing and commercializing novel therapeutics for pain, announced the start of a pivotal Phase 3 clinical trial in the U.S. to evaluate its lead product SP-102 in patients with lumbar radicular pain/sciatica. In addition, the U.S. Food and Drug Administration (FDA) has granted SP-102 Fast Track Designation for the treatment of lumbar radicular pain/sciatica. READ MORE »